{"organizations": [], "uuid": "4b1a9b3bd7f5f032c545b10ce95aca086716c155", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/us-rigel-pharms-fda/fda-approves-rigel-pharmaceuticals-drug-for-rare-bleeding-disorder-idUSKBN1HO2TV", "country": "US", "domain_rank": 408, "title": "FDA approves Rigel Pharmaceuticals' drug for rare bleeding disorder", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T20:59:00.000+03:00", "replies_count": 0, "uuid": "4b1a9b3bd7f5f032c545b10ce95aca086716c155"}, "author": "", "url": "https://www.reuters.com/article/us-rigel-pharms-fda/fda-approves-rigel-pharmaceuticals-drug-for-rare-bleeding-disorder-idUSKBN1HO2TV", "ord_in_thread": 0, "title": "FDA approves Rigel Pharmaceuticals' drug for rare bleeding disorder", "locations": [], "entities": {"persons": [{"name": "rigel", "sentiment": "none"}, {"name": "anil d'silva", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "rigel pharmaceuticals", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "rigel pharmaceuticals inc", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Rigel Pharmaceuticals Inc’s treatment for a rare bleeding disorder.\nRigel’s Tavalisse was approved to treat patients with immune thrombocytopenic purpura, a disease characterized by excessive bruising and bleeding caused by unusually low levels of platelets, which are integral to clotting.\nReporting by Tamara Mathias in Bengaluru; Editing by Anil D'Silva\n ", "external_links": [], "published": "2018-04-17T20:59:00.000+03:00", "crawled": "2018-04-17T21:12:46.026+03:00", "highlightTitle": ""}